COVID-19住院后2-3年认知与精神症状轨迹:英国纵向前瞻性队列研究
该研究纳入475例COVID-19住院患者,在出院后2-3年随访发现认知评分低于基于社会人口学特征的预期,多数报告至少轻度抑郁、焦虑、疲劳或主观认知下降,且这些症状较6个月或12个月时更差。2-3年症状不由急性期严重程度预测,而由6个月恢复程度等预测;职业变更常见且与客观和主观认知缺陷相关。
要点
- COVID-19住院后2-3年,抑郁、焦虑、疲劳较6个月或12个月更差,既有症状加重也有新发症状。
- 2-3年症状不由急性COVID-19严重程度预测,而由6个月恢复程度等预测。
- 职业变更报告率为26.9%,与客观认知缺陷(OR 1.51)和主观认知下降(OR 1.54)相关。
核心结论
- 精神与认知症状在住院后2-3年内似乎增加,源于6个月时已有症状的加重和新症状的出现。
- 新症状多出现在6个月时已有其他症状者中。
- 职业变更常见,主要与客观和主观认知缺陷相关。
- 作者认为早期识别和管理症状可能是预防后期复杂综合征的有效策略。
- 作者认为需要干预以促进认知恢复或预防认知下降,从而限制COVID-19的功能和经济影响。
研究设计与样本
- PHOSP-COVID为前瞻性纵向队列研究,纳入英国参与NHS医院住院且临床诊断COVID-19的成人(≥18岁)。
- C-Fog研究邀请同意再次联系的PHOSP-COVID参与者,在住院后2至3年完成计算机化认知评估和临床量表。
- 475例参与者(女性191例[40.2%],男性284例[59.8%];平均年龄58.26岁[SD 11.13])在2-3年随访时提供数据,来自83所医院出院。
- 评估工具包括Cognitron认知任务(8项任务覆盖8个认知域)、9项患者健康问卷、广泛性焦虑障碍7项量表、慢性病治疗功能评估疲劳量表、20项认知变化指数问卷和职业变更问卷。
- 分析症状在6个月、12个月和2-3年随访间的绝对风险演变,以及早期COVID-19疾病特征对2-3年症状的预测。
主要发现
- 所有测试认知域的认知评分均低于基于社会人口学特征的预期(平均低于均值0.71 SD [IQR 0.16-1.04];p<0.0001)。
- 353例中至少轻度抑郁263例(74.5%)、焦虑189例(53.5%)、疲劳220例(62.3%)、主观认知下降184例(52.1%)。
- 353例中严重抑郁79例(22.4%)、疲劳87例(24.6%)、主观认知下降88例(24.9%)。
- 抑郁、焦虑和疲劳在2-3年时较6个月或12个月时更差,既有现有症状加重也有新症状出现。
- 2-3年症状不由急性COVID-19严重程度预测,而由6个月恢复程度(解释焦虑、抑郁、疲劳和主观认知下降方差的35.0-48.8%)、生物认知特征(解释7.0-17.2%方差)及6个月时焦虑、抑郁、疲劳和主观认知缺陷预测;客观认知缺陷仅由6个月时认知缺陷预测(解释10.6%方差)。
关键数值与推荐
- 2-3年随访时,平均认知评分低于基于社会人口学特征的预期0.71 SD(IQR 0.16-1.04;p<0.0001)。
- 353例中至少轻度抑郁74.5%、焦虑53.5%、疲劳62.3%、主观认知下降52.1%;严重抑郁22.4%、疲劳24.6%、主观认知下降24.9%。
- 6个月恢复程度解释2-3年焦虑、抑郁、疲劳和主观认知下降方差的35.0-48.8%。
- 生物认知特征解释2-3年焦虑、抑郁、疲劳和主观认知下降方差的7.0-17.2%。
- 6个月认知缺陷解释2-3年客观认知缺陷方差的10.6%。
临床怎么用
- 作者认为早期识别和管理症状可能是预防后期复杂综合征的有效策略。
- 作者认为需要干预以促进认知恢复或预防认知下降,从而限制COVID-19的功能和经济影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 is known to be associated with increased risks of cognitive and psychiatric outcomes after the acute phase of disease. We aimed to assess whether these symptoms can emerge or persist more than 1 year after hospitalisation for COVID-19, to identify which early aspects of COVID-19 illness predict longer-term symptoms, and to establish how these symptoms relate to occupational functioning. METHODS: The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a prospective, longitudinal cohort study of adults (aged ≥18 years) who were hospitalised with a clinical diagnosis of COVID-19 at participating National Health Service hospitals across the UK. In the C-Fog study, a subset of PHOSP-COVID participants who consented to be recontacted for other research were invited to complete a computerised cognitive assessment and clinical scales between 2 years and 3 years after hospital admission. Participants completed eight cognitive tasks, covering eight cognitive domains, from the Cognitron battery, in addition to the 9-item Patient Health Questionnaire for depression, the Generalised Anxiety Disorder 7-item scale, the Functional Assessment of Chronic Illness Therapy Fatigue Scale, and the 20-item Cognitive Change Index (CCI-20) questionnaire to assess subjective cognitive decline. We evaluated how the absolute risks of symptoms evolved between follow-ups at 6 months, 12 months, and 2-3 years, and whether symptoms at 2-3 years were predicted by earlier aspects of COVID-19 illness. Participants completed an occupation change questionnaire to establish whether their occupation or working status had changed and, if so, why. We assessed which symptoms at 2-3 years were associated with occupation change. People with lived experience were involved in the study. FINDINGS: 2469 PHOSP-COVID participants were invited to participate in the C-Fog study, and 475 participants (191 [40·2%] females and 284 [59·8%] males; mean age 58·26 [SD 11·13] years) who were discharged from one of 83 hospitals provided data at the 2-3-year follow-up. Participants had worse cognitive scores than would be expected on the basis of their sociodemographic characteristics across all cognitive domains tested (average score 0·71 SD below the mean [IQR 0·16-1·04]; p<0·0001). Most participants reported at least mild depression (263 [74·5%] of 353), anxiety (189 [53·5%] of 353), fatigue (220 [62·3%] of 353), or subjective cognitive decline (184 [52·1%] of 353), and more than a fifth reported severe depression (79 [22·4%] of 353), fatigue (87 [24·6%] of 353), or subjective cognitive decline (88 [24·9%] of 353). Depression, anxiety, and fatigue were worse at 2-3 years than at 6 months or 12 months, with evidence of both worsening of existing symptoms and emergence of new symptoms. Symptoms at 2-3 years were not predicted by the severity of acute COVID-19 illness, but were strongly predicted by the degree of recovery at 6 months (explaining 35·0-48·8% of the variance in anxiety, depression, fatigue, and subjective cognitive decline); by a biocognitive profile linking acutely raised D-dimer relative to C-reactive protein with subjective cognitive deficits at 6 months (explaining 7·0-17·2% of the variance in anxiety, depression, fatigue, and subjective cognitive decline); and by anxiety, depression, fatigue, and subjective cognitive deficit at 6 months. Objective cognitive deficits at 2-3 years were not predicted by any of the factors tested, except for cognitive deficits at 6 months, explaining 10·6% of their variance. 95 of 353 participants (26·9% [95% CI 22·6-31·8]) reported occupational change, with poor health being the most common reason for this change. Occupation change was strongly and specifically associated with objective cognitive deficits (odds ratio [OR] 1·51 [95% CI 1·04-2·22] for every SD decrease in overall cognitive score) and subjective cognitive decline (OR 1·54 [1·21-1·98] for every point increase in CCI-20). INTERPRETATION: Psychiatric and cognitive symptoms appear to increase over the first 2-3 years post-hospitalisation due to both worsening of symptoms already present at 6 months and emergence of new symptoms. New symptoms occur mostly in people with other symptoms already present at 6 months. Early identification and management of symptoms might therefore be an effective strategy to prevent later onset of a complex syndrome. Occupation change is common and associated mainly with objective and subjective cognitive deficits. Interventions to promote cognitive recovery or to prevent cognitive decline are therefore needed to limit the functional and economic impacts of COVID-19. FUNDING: National Institute for Health and Care Research Oxford Health Biomedical Research Centre, Wolfson Foundation, MQ Mental Health Research, MRC-UK Research and Innovation, and National Institute for Health and Care Research.
引用
- Taquet M, Skorniewska Z, De Deyn T, et al. Cognitive and psychiatric symptom trajectories 2-3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. Lancet Psychiatry. 2024. PMID: 39096931. doi:10.1016/S2215-0366(24)00214-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。